Stockreport

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action [Yahoo! Finance]

Molecular Partners AG - American Depositary Shares  (MOLN) 
PDF MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial i [Read more]